Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Recursion is a clinical-stage TechBio company utilizing the Recursion Operating System (OS) to industrialize drug discovery through AI and wet-lab integration. The company operates as a single segment and has not yet commercialized any products. As of March 31, 2025, the company held an accumulated deficit of $1.6 billion.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $14,745 | $13,794 |
| Net Loss | $(202,487) | $(91,373) |
| Loss Per Share (Basic & Diluted) | $(0.50) | $(0.39) |
| Operating Cash Flow | $(131,957) | $(102,300) |
| Cash and Cash Equivalents (End of Period) | $500,453 | $306,150 |
| Total Debt (Notes & Leases) | $25,033 | $27,447 |
Liquidity: The company reported cash and cash equivalents of $500.5 million as of March 31, 2025. Management believes this is sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7% year-over-year to $14.7 million, driven by recognition from strategic partnerships with Sanofi and Merck.
- Expense Surge: Operating costs and expenses increased 87% to $206.1 million.
- R&D Expenses: Rose 92% to $129.6 million, primarily due to the inclusion of Exscientia operations (acquired Nov 2024) and $27.1 million in data purchases from Tempus.
- Cost of Revenue: Increased 96% to $21.8 million, largely attributable to the Exscientia acquisition.
- G&A Expenses: Increased 74% to $54.7 million, driven by Exscientia integration and higher personnel costs.
- Net Loss Expansion: Net loss more than doubled to $202.5 million, reflecting the significant increase in operating expenses.
- Other Income/Loss: Shifted from a net gain of $4.2 million in Q1 2024 to a net loss of $11.3 million in Q1 2025. This was due to a $4.5 million loss on the disposal of Exscientia GmbH and a $5.2 million lease termination fee related to Vienna facilities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Focus: The company is prioritizing high-value programs in oncology and rare diseases while discontinuing or seeking partners for lower-priority assets (e.g., REC-2282, REC-994).
- Pipeline Catalysts:
- REC-4881 (MEK1/2): Preliminary Phase 2 data showed a median 43% reduction in polyp burden in FAP patients.
- REC-7735 (PI3Kα): Preclinical data indicates potential for reduced hyperglycemia compared to standard-of-care; development candidate nomination expected in H2 2025.
- Partnerships: Received a $7 million milestone payment from Sanofi for a fourth partnered program. Collaboration with Roche/Genentech continues to generate phenomaps.
- Capital Needs: The company anticipates needing additional financing in the future to fund operations and potential commercialization. It maintains an At-The-Market (ATM) offering with Citigroup with $495.9 million remaining available.
Risks and Contingencies
- Internal Controls: Disclosure controls and procedures were deemed ineffective as of March 31, 2025, due to a material weakness in internal control over financial reporting related to revenue recognition cost models and the integration of Exscientia. Remediation is ongoing.
- Legal Proceedings:
- Putative class action lawsuits against Exscientia (pre-acquisition) alleging securities violations remain pending.
- Ongoing litigation with a landlord (Industry Office SLC, LLC) regarding construction defects and lease disputes.
- Regulatory and Trade: Risks related to export controls, trade sanctions, and tariffs, particularly involving China, could impact international operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $500.5 million cash balance against the current burn rate of ~$132 million per quarter.
- Internal Control Remediation: Monitor progress on remediating the material weakness in financial reporting controls, specifically regarding revenue recognition and Exscientia integration.
- Exscientia Integration: Assess the financial impact of the Exscientia acquisition, including the finalization of the purchase price allocation and the realization of synergies.
- Pipeline Milestones: Track upcoming data readouts for REC-4881 (H2 2025) and REC-7735 (H2 2025) to validate the AI-driven discovery platform.
- Legal Exposure: Review the status of the Exscientia class action lawsuits and the landlord dispute for potential financial liabilities.